The pharmaceutical inventory in Philadelphia is at its highest level in recent years, and that could be due to one mass tort program: Risperdal.

According to the First Judicial District’s most recent statistics regarding the mass tort litigation in Philadelphia’s Complex Litigation Center, 5,601 pharmaceutical cases were pending as of Jan. 1. That’s nearly 200 more pharmaceutical cases than were pending at the start of 2012—the year the court began implementing changes aimed at clearing its mass tort inventory.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]